Developer docs
API playgroundTry for free, no card

Search company profiles

UroGen Pharma

Full company profile

uuid0000msa

Namestring
UroGen Pharma
Legal namestring
UroGen Pharma Ltd. and UroGen Pharma, Inc.
Websiteurl
urogen.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

UroGen Pharma is a commercial-stage biopharmaceutical company specializing in urothelial cancers, with its corporate headquarters in Princeton, NJ and R&D operations in Ra'anana, Israel. The company is built around RTGel, a proprietary reverse-thermal hydrogel that exists as a liquid at low temperatures and transitions to a gel at body temperature, enabling sustained-release delivery of mitomycin directly into the urinary tract. This platform underpins two FDA-approved products: JELMYTO (mitomycin) for pyelocalyceal solution, approved April 2020 for low-grade upper tract urothelial cancer (LG-UTUC), and ZUSDURI (mitomycin) for intravesical solution, approved June 2025 as the first FDA-approved drug for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

UroGen commercializes its products in the United States through a direct field-based sales organization targeting urologists and oncology specialists, supported by reimbursement services (UroGen Support) and free administration supplies (Chilling Block, Uroject12, IVAK/UCAK kits). International distribution is handled through an exclusive license with Neopharm in Israel and a Named Patient Program administered by Tanner Pharma. The company has a multi-asset pipeline including UGN-102 (NDA under FDA review), UGN-103 and UGN-104 (next-generation RTGel + medac lyophilized mitomycin formulations), and UGN-501 (an oncolytic virus acquired from IconOVir Bio in February 2025 for high-grade NMIBC).

UroGen is publicly traded on NASDAQ under ticker URGN. The company has funded operations through a mix of equity (~$107.5M public offering in June 2024) and non-dilutive debt (Pharmakon Advisors: $100M in 2022, expanded to up to $250M in Q1 2026). Full-year 2025 revenue was $109.8M (+21% YoY), with Q1 2026 revenue of $51.0M (+152% YoY) reflecting the ZUSDURI launch ramp; the company remains unprofitable with a 2025 net loss of -$153.5M. ZUSDURI carries an 88.66% gross margin and management cites peak sales potential exceeding $1 billion by 2030.

Short descriptiontext

UroGen Pharma is a commercial-stage biopharmaceutical company that develops and commercializes RTGel reverse-thermal hydrogel-based mitomycin therapies for urothelial cancers, with two FDA-approved products (JELMYTO, ZUSDURI) serving US urologists and oncology specialists treating low-grade upper tract urothelial cancer and recurrent non-muscle invasive bladder cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
urological cancer therapies, bladder cancer treatment, urothelial cancer drugs, hydrogel drug delivery, specialty oncology pharmaceuticals
Industry3 codes
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Urological Oncology Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - ZUSDURI
TypeOne Time License
Description

ZUSDURI (mitomycin) for intravesical solution, FDA-approved for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Generated $29.2M in Q1 2026 revenue, representing 109% quarter-over-quarter growth. Full-year 2025 net product revenue was $15.8M.

stocktitan.net
2Product Sales - JELMYTO
TypeOne Time License
Description

JELMYTO (mitomycin) for pyelocalyceal solution, FDA-approved for low-grade upper tract urothelial cancer. Achieved $94M in net product sales in 2025, up from $90.4M in 2024, with Q1 2026 revenue of $21.7M representing 7% year-over-year growth.

investing.com
3International Licensing - Neopharm (Israel)
TypeLicensing Royalties
Description

Exclusive license and supply agreement with Neopharm Group to market and sell JELMYTO in Israel. JELMYTO is approved by Israeli Ministry of Health for treatment of adult patients with low-grade Upper Tract Urothelial Cancer.

urogen.com
4Named Patient Program - Tanner Pharma
TypeLicensing Royalties
Description

Named Patient Program administered by Tanner Pharma Group providing controlled, pre-approval access to JELMYTO in select countries where JELMYTO is not yet available or approved, in response to unsolicited requests by physicians on behalf of specific patients.

urogen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1RTGel
Description

Proprietary reverse-thermal hydrogel technology platform that enables sustained-release drug delivery for urological treatments

urogen.com
+2 more records
Core offering1 text field

UroGen Pharma develops and commercializes FDA-approved pharmaceutical therapies for urothelial and specialty urological cancers using its proprietary RTGel reverse-thermal hydrogel technology platform. The company sells two FDA-approved mitomycin-based drugs—JELMYTO for low-grade upper tract urothelial cancer (LG-UTUC) and ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)—along with associated administration devices to urologists and oncology specialists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 64.5% probability of remaining event-free at 36 months in patients achieving complete response at 3 months (79.6%)
+4 more records
Product overview1 text field

UroGen Pharma is a biotechnology company developing and commercializing innovative solutions for urothelial and specialty cancers. The company offers two FDA-approved products leveraging its proprietary RTGel reverse-thermal hydrogel technology: Jelmyto (approved April 2020) for low-grade upper tract urothelial cancer and Zusduri (approved June 2025) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both products provide non-surgical tumor ablation options. The pipeline includes UGN-102 (NDA under FDA review), UGN-103 (Phase 3 completed, NDA submission planned 2026), UGN-104 (Phase 3 enrolling), and UGN-501 (acquired oncolytic virus in IND-enabling stage). The company also provides associated medical devices and administration kits including the Chilling Block, Uroject12, and catheter administration kits.

Product and service2 records
1JELMYTO (mitomycin) for pyelocalyceal solution
CategoryPharmaceutical - Urological Oncology
Description

FDA-approved mitomycin-based therapy using RTGel reverse-thermal hydrogel technology for non-surgical tumor ablation in adult patients with low-grade upper tract urothelial cancer (LG-UTUC). First and only treatment of its kind, administered by urologists via ureteral catheter.

2ZUSDURI (mitomycin) for intravesical solution
CategoryPharmaceutical - Urological Oncology
Description

FDA-approved mitomycin-based therapy using RTGel reverse-thermal hydrogel technology for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), offering a non-surgical alternative to repeated TURBT procedures.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1IconOVir Bio
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

UroGen acquired ICVB-1042 (now known as UGN-501) from IconOVir Bio in February 2025 for $4 million. UGN-501 is a next-generation investigational oncolytic virus for high-grade non-muscle invasive bladder cancer, engineered for efficient cell entry, strong selectivity for malignant cells, and rapid replication in tumor microenvironment.

labiotech.eu
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-01
Description

License and supply agreement for next-generation products combining RTGel technology with medac's proprietary lyophilized mitomycin formulation. Includes UGN-103 (80mg formulation for LG-IR-NMIBC) and UGN-104 (for LG-UTUC). medac patents with protection until 2035; UroGen has separate patents expiring December 2041.

3Neopharm Group
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive license and supply agreement to market and sell Jelmyto in Israel. JELMYTO is approved by Israeli Ministry of Health for treatment of adult patients with low-grade Upper Tract Urothelial Cancer and is available in Israel. Neopharm is part of privately owned group operating in healthcare in more than 60 countries.

urogen.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Tanner Pharma Group administers Named Patient Program for Jelmyto in select countries where Jelmyto is not yet available or approved. Provides controlled, pre-approval access in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, or ministries of health on behalf of specific patients.

Strategic tierTerminatedTypeOEM/ Whitelabel/ Licensing Partner
Description

License agreement for anti-CTLA-4 drug zalifrelimab (UGN-301). UroGen terminated the agreement in November 2025 after Phase 1 data did not meet internal benchmarks for advancement. Termination effective upon expiration of 180-day notice period.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Bristol-Myers Squibb
TypeBroad incumbent
Description

Markets Opdivo (nivolumab) for NMIBC indications and competes in the broader urologic oncology space. Overlaps with UroGen's NMIBC patient population as part of a diversified oncology and specialty franchise.

TypeDirect peer
Description

Received FDA approval for Anktiva (nogapendekin alfa inbakicept-pmln) in NMIBC, a novel IL-15 superagonist intravesical therapy. Competes head-to-head in the NMIBC space, particularly in BCG-unresponsive settings where UroGen's products also compete.

TypeBroad incumbent
Description

Markets Imfinzi (durvalumab) and other immuno-oncology agents with relevance in bladder and urologic cancers. A broad oncology incumbent whose bladder-cancer indications intersect with UroGen's target NMIBC population.

TypeOthers
Description

Settled UroGen's JELMYTO patent litigation in June 2026 and obtained a non-exclusive license to launch a generic JELMYTO on September 15, 2030. Relevant as the future generic entrant whose entry will directly pressure UroGen's legacy UTUC franchise.

TypeOthers
Description

Specializes in urologic cancer genomic diagnostics (e.g., Decipher Prostate, Afirma). Adjacent ecosystem participant that serves the same urologist and oncology specialist customer base and could be a strategic partner or comparable in the urologic oncology workflow.

TypeBroad incumbent
Description

Markets Keytruda (pembrolizumab) for BCG-unresponsive NMIBC and other urologic cancers. Competes with UroGen in the NMIBC treatment paradigm but as a broad-based oncology immuno-oncology leader rather than a urology specialist.

TypeDirect peer
Description

Markets Hexvix/Cysview, a blue-light cystoscopy agent used in bladder cancer detection and management of NMIBC. Comparable because it serves the same urologist prescribers and NMIBC patient flow that UroGen's ZUSDURI and JELMYTO address.

TypeDirect peer
Description

Clinical- and commercial-stage immuno-oncology company developing cretostimogene grenadenorepvec for BCG-unresponsive NMIBC. Most directly comparable competitor in the same intravesical NMIBC treatment space, targeting overlapping urologist prescribers.

TypeBroad incumbent
Description

Developing TAR-200, a gemcitabine-releasing intravesical system for NMIBC, leveraging J&J's large oncology and urology commercial footprint. Competes for the same NMIBC patients and urologist prescribing slots as UroGen, but as part of a much broader oncology/urology portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UroGen Pharma

Urological Oncology Pharmaceuticalsurogen.com

UroGen Pharma is a commercial-stage biopharmaceutical company that develops and commercializes RTGel reverse-thermal hydrogel-based mitomycin therapies for urothelial cancers, with two FDA-approved products (JELMYTO, ZUSDURI) serving US urologists and oncology specialists treating low-grade upper tract urothelial cancer and recurrent non-muscle invasive bladder cancer.

What UroGen Pharma does

UroGen Pharma is a commercial-stage biopharmaceutical company specializing in urothelial cancers, with its corporate headquarters in Princeton, NJ and R&D operations in Ra'anana, Israel. The company is built around RTGel, a proprietary reverse-thermal hydrogel that exists as a liquid at low temperatures and transitions to a gel at body temperature, enabling sustained-release delivery of mitomycin directly into the urinary tract. This platform underpins two FDA-approved products: JELMYTO (mitomycin) for pyelocalyceal solution, approved April 2020 for low-grade upper tract urothelial cancer (LG-UTUC), and ZUSDURI (mitomycin) for intravesical solution, approved June 2025 as the first FDA-approved drug for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

UroGen commercializes its products in the United States through a direct field-based sales organization targeting urologists and oncology specialists, supported by reimbursement services (UroGen Support) and free administration supplies (Chilling Block, Uroject12, IVAK/UCAK kits). International distribution is handled through an exclusive license with Neopharm in Israel and a Named Patient Program administered by Tanner Pharma. The company has a multi-asset pipeline including UGN-102 (NDA under FDA review), UGN-103 and UGN-104 (next-generation RTGel + medac lyophilized mitomycin formulations), and UGN-501 (an oncolytic virus acquired from IconOVir Bio in February 2025 for high-grade NMIBC).

UroGen is publicly traded on NASDAQ under ticker URGN. The company has funded operations through a mix of equity (~$107.5M public offering in June 2024) and non-dilutive debt (Pharmakon Advisors: $100M in 2022, expanded to up to $250M in Q1 2026). Full-year 2025 revenue was $109.8M (+21% YoY), with Q1 2026 revenue of $51.0M (+152% YoY) reflecting the ZUSDURI launch ramp; the company remains unprofitable with a 2025 net loss of -$153.5M. ZUSDURI carries an 88.66% gross margin and management cites peak sales potential exceeding $1 billion by 2030.

UroGen Pharma firmographics

Firmographics
Name
UroGen Pharma
Legal name
UroGen Pharma Ltd. and UroGen Pharma, Inc.
Website
https://urogen.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
251–500 employees
Short description
UroGen Pharma is a commercial-stage biopharmaceutical company that develops and commercializes RTGel reverse-thermal hydrogel-based mitomycin therapies for urothelial cancers, with two FDA-approved products (JELMYTO, ZUSDURI) serving US urologists and oncology specialists treating low-grade upper tract urothelial cancer and recurrent non-muscle invasive bladder cancer.
Ownership category
akta.pro rank

UroGen Pharma industry classification

Industry
Product category
Urological Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Urological cancer therapies
  • Bladder cancer treatment
  • Urothelial cancer drugs
  • Hydrogel drug delivery
  • Specialty oncology pharmaceuticals

Where UroGen Pharma is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices3 records

Markets served

UroGen Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

  1. Product Sales - ZUSDURI: ZUSDURI (mitomycin) for intravesical solution, FDA-approved for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Generated $29.2M in Q1 2026 revenue, representing 109% quarter-over-quarter growth. Full-year 2025 net product revenue was $15.8M.
  2. Product Sales - JELMYTO: JELMYTO (mitomycin) for pyelocalyceal solution, FDA-approved for low-grade upper tract urothelial cancer. Achieved $94M in net product sales in 2025, up from $90.4M in 2024, with Q1 2026 revenue of $21.7M representing 7% year-over-year growth.
  3. International Licensing - Neopharm (Israel): Exclusive license and supply agreement with Neopharm Group to market and sell JELMYTO in Israel. JELMYTO is approved by Israeli Ministry of Health for treatment of adult patients with low-grade Upper Tract Urothelial Cancer.
  4. Named Patient Program - Tanner Pharma: Named Patient Program administered by Tanner Pharma Group providing controlled, pre-approval access to JELMYTO in select countries where JELMYTO is not yet available or approved, in response to unsolicited requests by physicians on behalf of specific patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

UroGen Pharma product offering

Product offering

Core offering

UroGen Pharma develops and commercializes FDA-approved pharmaceutical therapies for urothelial and specialty urological cancers using its proprietary RTGel reverse-thermal hydrogel technology platform. The company sells two FDA-approved mitomycin-based drugs—JELMYTO for low-grade upper tract urothelial cancer (LG-UTUC) and ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)—along with associated administration devices to urologists and oncology specialists.

Product overview

UroGen Pharma is a biotechnology company developing and commercializing innovative solutions for urothelial and specialty cancers. The company offers two FDA-approved products leveraging its proprietary RTGel reverse-thermal hydrogel technology: Jelmyto (approved April 2020) for low-grade upper tract urothelial cancer and Zusduri (approved June 2025) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both products provide non-surgical tumor ablation options. The pipeline includes UGN-102 (NDA under FDA review), UGN-103 (Phase 3 completed, NDA submission planned 2026), UGN-104 (Phase 3 enrolling), and UGN-501 (acquired oncolytic virus in IND-enabling stage). The company also provides associated medical devices and administration kits including the Chilling Block, Uroject12, and catheter administration kits.

Differentiator

Problem solved

Functional benefit

Brands

  • RTGel: Proprietary reverse-thermal hydrogel technology platform that enables sustained-release drug delivery for urological treatments
  • JELMYTO
  • ZUSDURI

Products and services

  • JELMYTO (mitomycin) for pyelocalyceal solution FDA-approved mitomycin-based therapy using RTGel reverse-thermal hydrogel technology for non-surgical tumor ablation in adult patients with low-grade upper tract urothelial cancer (LG-UTUC). First and only treatment of its kind, administered by urologists via ureteral catheter.
  • ZUSDURI (mitomycin) for intravesical solution FDA-approved mitomycin-based therapy using RTGel reverse-thermal hydrogel technology for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), offering a non-surgical alternative to repeated TURBT procedures.

Quantifiable outcome

  • 64.5% probability of remaining event-free at 36 months in patients achieving complete response at 3 months (79.6%)
  • +4 more outcomes

Companies that use UroGen Pharma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

UroGen Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

UroGen Pharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic, core, regional, minor and terminated.

  • IconOVir BiostrategicStrategic or Co-development Partner · 1 February 2025UroGen acquired ICVB-1042 (now known as UGN-501) from IconOVir Bio in February 2025 for $4 million. UGN-501 is a next-generation investigational oncolytic virus for high-grade non-muscle invasive bladder cancer, engineered for efficient cell entry, strong selectivity for malignant cells, and rapid replication in tumor microenvironment.
  • medac GmbHcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2024License and supply agreement for next-generation products combining RTGel technology with medac's proprietary lyophilized mitomycin formulation. Includes UGN-103 (80mg formulation for LG-IR-NMIBC) and UGN-104 (for LG-UTUC). medac patents with protection until 2035; UroGen has separate patents expiring December 2041.
  • Neopharm GroupregionalChannel Partner/ Reseller/ DistributorExclusive license and supply agreement to market and sell Jelmyto in Israel. JELMYTO is approved by Israeli Ministry of Health for treatment of adult patients with low-grade Upper Tract Urothelial Cancer and is available in Israel. Neopharm is part of privately owned group operating in healthcare in more than 60 countries.
  • Tanner Pharma GroupminorChannel Partner/ Reseller/ DistributorTanner Pharma Group administers Named Patient Program for Jelmyto in select countries where Jelmyto is not yet available or approved. Provides controlled, pre-approval access in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, or ministries of health on behalf of specific patients.
  • Agenus Inc.terminatedOEM/ Whitelabel/ Licensing PartnerLicense agreement for anti-CTLA-4 drug zalifrelimab (UGN-301). UroGen terminated the agreement in November 2025 after Phase 1 data did not meet internal benchmarks for advancement. Termination effective upon expiration of 180-day notice period.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

UroGen Pharma competitors and assessment

Company assessment

Broad incumbents

  • Bristol-Myers Squibb: Markets Opdivo (nivolumab) for NMIBC indications and competes in the broader urologic oncology space. Overlaps with UroGen's NMIBC patient population as part of a diversified oncology and specialty franchise.
  • AstraZeneca: Markets Imfinzi (durvalumab) and other immuno-oncology agents with relevance in bladder and urologic cancers. A broad oncology incumbent whose bladder-cancer indications intersect with UroGen's target NMIBC population.
  • Merck & Co. Markets Keytruda (pembrolizumab) for BCG-unresponsive NMIBC and other urologic cancers. Competes with UroGen in the NMIBC treatment paradigm but as a broad-based oncology immuno-oncology leader rather than a urology specialist.
  • Johnson & Johnson: Developing TAR-200, a gemcitabine-releasing intravesical system for NMIBC, leveraging J&J's large oncology and urology commercial footprint. Competes for the same NMIBC patients and urologist prescribing slots as UroGen, but as part of a much broader oncology/urology portfolio.

Direct peers

  • ImmunityBio: Received FDA approval for Anktiva (nogapendekin alfa inbakicept-pmln) in NMIBC, a novel IL-15 superagonist intravesical therapy. Competes head-to-head in the NMIBC space, particularly in BCG-unresponsive settings where UroGen's products also compete.
  • Photocure: Markets Hexvix/Cysview, a blue-light cystoscopy agent used in bladder cancer detection and management of NMIBC. Comparable because it serves the same urologist prescribers and NMIBC patient flow that UroGen's ZUSDURI and JELMYTO address.
  • CG Oncology: Clinical- and commercial-stage immuno-oncology company developing cretostimogene grenadenorepvec for BCG-unresponsive NMIBC. Most directly comparable competitor in the same intravesical NMIBC treatment space, targeting overlapping urologist prescribers.

Others

  • Teva Pharmaceutical Industries: Settled UroGen's JELMYTO patent litigation in June 2026 and obtained a non-exclusive license to launch a generic JELMYTO on September 15, 2030. Relevant as the future generic entrant whose entry will directly pressure UroGen's legacy UTUC franchise.
  • Veracyte: Specializes in urologic cancer genomic diagnostics (e.g., Decipher Prostate, Afirma). Adjacent ecosystem participant that serves the same urologist and oncology specialist customer base and could be a strategic partner or comparable in the urologic oncology workflow.
  • Pfizer (via prior Allergan Aesthetics / Ferring-derived Adstiladrin):

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

UroGen Pharma social profiles

Digital presence

UroGen Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UroGen Pharma leadership team

Management profile

Number of profiles

Profiles9 records

UroGen Pharma funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UroGen Pharma M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UroGen Pharma

What does UroGen Pharma do?

UroGen Pharma develops and commercializes FDA-approved pharmaceutical therapies for urothelial and specialty urological cancers using its proprietary RTGel reverse-thermal hydrogel technology platform. The company sells two FDA-approved mitomycin-based drugs—JELMYTO for low-grade upper tract urothelial cancer (LG-UTUC) and ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)—along with associated administration devices to urologists and oncology specialists.

Is UroGen Pharma a public or private company?

UroGen Pharma is a public company. It is classified as public and is currently operating.

When was UroGen Pharma founded?

UroGen Pharma was founded in 2020. It employs 251 to 500 people.

Where is UroGen Pharma based?

UroGen Pharma is headquartered in Princeton, United States, in the North America region.

How does UroGen Pharma make money?

Four revenue lines are on record. Product Sales - ZUSDURI is the primary driver. The others are product Sales - JELMYTO, international Licensing - Neopharm (Israel) and named Patient Program - Tanner Pharma.

Who are UroGen Pharma's main competitors?

Broad incumbents on record are Bristol-Myers Squibb, AstraZeneca, Merck & Co. and Johnson & Johnson. Direct peers are ImmunityBio, Photocure and CG Oncology. Others are Teva Pharmaceutical Industries, Veracyte and Pfizer (via prior Allergan Aesthetics / Ferring-derived Adstiladrin).

Does UroGen Pharma have an API?

No public API is recorded for UroGen Pharma.

What industry is UroGen Pharma in?

UroGen Pharma's product category is Urological Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooUroGen Pharma (URGN) Stock Could Be A Bargain Following Its 148% RunUroGen Pharma's stock has returned about 148% over five years, and its P/S ratio of 5.9x is below the biotech industry average of 9.8x and peer group near 17.6x. The stock screens as undervalued on a sales-based framework, with analysts' numbers suggesting potential upside.Seeking AlphaUroGen: Opportunity Builds As Rough Patch Gets Brutal (NASDAQ:URGN)UroGen Pharma's stock fell after Q3 2026 earnings, but the author rates it a Buy, citing a depressed market cap of ~$1.21 billion. He estimates ZUSDURI could reach $572 million in 2031 sales, implying a ~$2 billion fair value. The company expects profitability by Q4 2026.American Banking and Market NewsFY2026 EPS Estimate for Urogen Pharma Lifted by AnalystHC Wainwright raised its FY2026 EPS estimate for Urogen Pharma to -$0.77 from -$0.83, keeping a Buy rating and $75 target. The company reported Q4 2026 EPS of -$0.03, missing the $0.11 consensus, with revenue of $89 million versus $89.92 million expected.Simply Wall StUroGen Pharma Ltd. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen NextUroGen Pharma reported a statutory loss of $0.03 per share on $89m revenue, despite analysts expecting a profit. Analysts now forecast $539.7m revenue and $2.76 EPS for 2027, with a price target of $61.71. The company is expected to grow faster than the industry.Investing.comOppenheimer reiterates Outperform on UroGen Pharma stock at $60Oppenheimer reiterated an Outperform rating and $60 price target on UroGen Pharma after its Q3 results. The company reported Zusduri sales of $68 million, up 35% from the prior quarter, exceeding estimates. Oppenheimer expects sequential growth in Q4 to drive consistent profitability.The Motley FoolThe Gel That Became a BusinessUroGen Pharma reported Q4 revenue of $89 million, with ZUSDURI generating $68 million, up 35% from the prior quarter. The company expects to turn a profit in Q4, though ZUSDURI growth is slowing. Management raised full-year expense guidance to $260–270 million.Investing.comWhy is UroGen Pharma stock sliding today?UroGen Pharma shares fell 16.5% after Q3 2026 results showed revenue of $89 million, below the $90.58 million forecast, and a cut in JELMYTO guidance to about $90 million. R&D expenses jumped 86% to $26 million, and the stock's decline was company-specific amid a positive broader market.TradingViewUroGen Pharma Q3 2026 Earnings Call Is LiveUroGen Pharma's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.ChartmillUroGen Pharma (NASDAQ:URGN) Falls After Q3 Revenue Miss and JELMYTO Guidance CutUroGen Pharma reported Q3 2026 revenue of $89.0 million, missing the $91.7 million consensus, and a net loss of $1.5 million versus a $33.3 million loss a year earlier. It cut its full-year JELMYTO revenue guidance to about $90 million from $97–101 million, and the stock fell about 8.1% in premarket trading.Quiver QuantitativeUROGEN PHARMA ($URGN) Releases Q3 2026 Earnings | URGN Stock NewsUROGEN PHARMA reported Q3 2026 earnings of -$0.03 per share, missing estimates by $0.17, and revenue of $89 million, missing by $2.7 million. Insiders made seven sales and no purchases in the past six months, while 108 institutional investors added shares and 65 reduced positions.